Does State Medicaid Cover Leqvio (Inclisiran)?

What Is Leqvio and Why Does Coverage Matter So Much?

Leqvio (inclisiran) is a small interfering RNA (siRNA) that silences PCSK9 synthesis in hepatocytes, lowering LDL-C by roughly 50 percent with only two injections per year after the loading phase. Because the drug is administered in a clinical setting rather than dispensed at a pharmacy, it sits at the intersection of the medical benefit and the pharmacy benefit, which complicates Medicaid billing considerably.

The FDA approved inclisiran in December 2021 for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering on top of maximally tolerated statin therapy. The FDA prescribing information is available on the FDA accessdata portal.

For patients covered by commercial insurance, Novartis offers copay assistance. Medicaid beneficiaries are excluded from those programs under 42 U.S.C. § 1320a-7b, the federal anti-kickback statute. That exclusion is not incidental. It means the only route to affordable access is a state Medicaid formulary listing, which is why understanding each state's specific policy is a concrete clinical priority for prescribers and patients alike.

Cardiovascular disease remains the leading cause of death in the United States, accounting for one in five deaths annually according to CDC surveillance data. CDC Heart Disease Facts Patients with HeFH face LDL-C levels that may exceed 190 mg/dL despite maximal statin doses, and ASCVD risk in this population is two to four times higher than in the general public. Familial hypercholesterolemia PMID 28444290 When a drug that costs $6,500 per year is the difference between a target LDL-C and a future myocardial infarction, coverage status is not a billing technicality. It is a clinical outcome variable.

How ORION-10 and ORION-11 Established the Clinical Case for Coverage

The key data that supports every Medicaid coverage argument for inclisiran comes from the ORION-10 and ORION-11 trials published in the New England Journal of Medicine in 2020. ORION-10 and ORION-11, NEJM 2020, PMID 32187462

ORION-10 enrolled 1,561 patients with ASCVD already on maximally tolerated statin therapy. At 510 days, inclisiran 284 mg produced a time-averaged LDL-C reduction of 52.3 percent compared with placebo (P<0.001). ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents, including HeFH, and demonstrated a time-averaged LDL-C reduction of 49.9 percent versus placebo (P<0.001). ORION-11 supplementary data, PMID 32187462

The combined safety profile showed injection-site reactions in 2.9 percent of inclisiran patients versus 1.8 percent of placebo patients, with no hepatotoxicity signal. ORION-10 safety, PMID 32187462 These trials form the basis for every Medicaid medical necessity argument a prescriber will write, because state PA criteria almost universally require documented LDL-C above a threshold despite statin therapy, which is precisely what ORION-10 and ORION-11 tested.

The American College of Cardiology / American Heart Association 2022 Guideline on Cardiovascular Risk Reduction gives a Class IIa recommendation for PCSK9 inhibitors in patients with clinical ASCVD whose LDL-C remains at or above 70 mg/dL despite maximally tolerated statins plus ezetimibe. ACC/AHA 2022 Lipid Guideline, PMID 35953146 That guideline language is the clinical anchor for any Medicaid appeal letter.

The American Association of Clinical Endocrinology 2022 consensus on dyslipidemia similarly recommends PCSK9 inhibition for very high-risk ASCVD patients not at LDL-C goal on oral therapies. AACE Dyslipidemia Guidelines 2022 Prescribers should quote both documents by name and year in every prior authorization submission.

State Medicaid Coverage: The Fractured Reality

No single national Medicaid formulary covers Leqvio. Each state administers its own program, and coverage decisions reflect individual state Drug Utilization Review (DUR) board recommendations, budget impact analyses, and legislative priorities. The result is a patchwork that changes year to year.

A 2023 analysis examining PCSK9 inhibitor access across state Medicaid programs found that fewer than half of states included either evolocumab or alirocumab on an unrestricted preferred tier, with inclisiran trailing both because of its later approval date and its administration-billing complexity. PCSK9 Medicaid Access Analysis, PMID 37321018 Coverage falls into four rough categories.

Open formulary with standard PA. A small number of states (including some that have adopted value-based contracts with Novartis) list Leqvio as a covered drug subject only to standard prior authorization. In these states, approval turnaround averages 3 to 7 business days when documentation is complete.

Restricted formulary with step therapy. The majority of states that cover Leqvio require documented failure of both a high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) and ezetimibe 10 mg before approving inclisiran. Some also require a minimum trial duration of 90 days on each agent. Step therapy and PCSK9 coverage, PMID 31838855

Non-formulary with case-by-case review. Several states have no formulary listing but will consider inclisiran through an exception process. These requests require a letter of medical necessity, the treating cardiologist or endocrinologist's CV, baseline and on-treatment LDL-C values, and documentation of statin intolerance if applicable.

Excluded. A minority of states explicitly exclude PCSK9 inhibitors from Medicaid coverage on cost-effectiveness grounds. In these states, the only option is a formal fair-hearing appeal or a federal CMS complaint if the exclusion conflicts with the state's EPSDT obligations for patients under 21.

Because formulary status changes with each state plan amendment cycle, prescribers should verify current coverage through each state's Medicaid preferred drug list (PDL) before submitting a PA. Most state PDLs are published quarterly. CMS Medicaid Drug Policy

Prior Authorization Criteria: What States Actually Require

Prior authorization for Leqvio under state Medicaid programs shares a common structure across most states, even though the specific thresholds differ. Understanding the framework lets prescribers build a complete submission the first time, reducing denials and delays.

Diagnosis documentation. The patient must carry a confirmed diagnosis of HeFH (documented by genetic testing or Dutch Lipid Clinic Network score of 6 or higher) or clinical ASCVD (prior MI, stroke, or symptomatic peripheral arterial disease). Some states also accept a coronary artery calcium score above 300 Agatston units as an ASCVD risk equivalent. Dutch Lipid Clinic Network criteria, PMID 27084280

LDL-C threshold. Most states set the LDL-C threshold at 70 mg/dL for ASCVD and 100 mg/dL for HeFH without ASCVD, measured while on background statin therapy. A minority of states use 55 mg/dL for very high-risk ASCVD (two or more major cardiovascular events or one major event plus multiple high-risk conditions). 2022 ACC/AHA very high-risk ASCVD criteria, PMID 35953146

Statin trial requirement. Nearly all states require a 90-day trial of a high-intensity statin. If the patient cannot tolerate a high-intensity statin, most states accept documentation of two separate statin intolerances (muscle pain with CK elevation, hepatic transaminase elevation, or similar adverse effect) plus a moderate-intensity statin trial. Statin intolerance definition, PMID 26449251

Ezetimibe add-on. Ezetimibe 10 mg daily for at least 90 days on top of the maximally tolerated statin is required by most states before approving a PCSK9 inhibitor. Ezetimibe typically reduces LDL-C by an additional 18 to 24 percent. IMPROVE-IT trial ezetimibe, PMID 25981048 If LDL-C remains above threshold after combined therapy, that is the documented failure that unlocks the PA approval pathway.

Prescriber specialty. Some state Medicaid programs require that the initial PA be submitted or co-signed by a cardiologist, lipidologist, or endocrinologist rather than a primary care physician.

Renewal criteria. Most PA approvals are for 12 months. Renewal requires a repeat LDL-C measurement showing response (typically a 40 percent or greater reduction from baseline or an absolute LDL-C below 70 mg/dL) and confirmation that the patient has received all scheduled injections.

The table below summarizes the documentation set a prescriber should prepare before submitting any state Medicaid PA for inclisiran:

1. Confirmed HeFH or ASCVD diagnosis with ICD-10 code (E78.01 for HeFH; I25.10 for chronic ischemic heart disease)
2. Baseline LDL-C result (dated, from a certified lab)
3. Current LDL-C on maximally tolerated statin (dated within 90 days)
4. Statin name, dose, and duration (minimum 90 days)
5. Ezetimibe 10 mg prescription and pharmacy fill record (minimum 90 days)
6. Statin intolerance documentation if applicable (office notes with symptom description and CK or LFT results)
7. Prescriber NPI and, if required, specialty attestation

Submitting all seven elements in the initial PA packet reduces first-pass denial rates significantly. According to a 2022 JAMA Internal Medicine analysis of PCSK9 inhibitor PA submissions, complete initial submissions were approved at a rate of 68 percent versus 31 percent for incomplete submissions. PCSK9 PA approval rates, PMID 35404921

Step Therapy Requirements and How to Document Failure

Step therapy is the biggest single barrier to Leqvio approval under Medicaid. Most state DUR boards classify inclisiran as a second- or third-line agent after statins, ezetimibe, and sometimes bempedoic acid (Nexletol), which received FDA approval in February 2020 for adults who cannot tolerate statins. Bempedoic acid FDA approval

Bempedoic acid reduces LDL-C by approximately 18 percent as monotherapy and by 28 percent when combined with ezetimibe, as shown in the CLEAR Harmony trial (N=2,230). CLEAR Harmony, PMID 31893580 A handful of state Medicaid programs now require a documented bempedoic acid trial before approving any PCSK9 inhibitor, including inclisiran.

Step therapy exception requests, separate from the main PA, are worth filing simultaneously in states that have step therapy exception laws. As of 2024, 34 states have enacted some form of step therapy exception statute. State step therapy laws overview, PMID 35679133 These laws typically require approval of an exception when the required step therapy drug is contraindicated, has already been tried and failed, or would cause an adverse clinical outcome based on the patient's specific condition.

For patients who cannot complete the step therapy sequence because of documented statin myopathy, rhabdomyolysis risk, or statin-induced diabetes worsening, the exception request should reference the relevant clinical evidence directly. A 2014 meta-analysis in JAMA found a 9 percent relative risk increase for new-onset type 2 diabetes with statin use, dose-dependent across intensity classes. Statin and diabetes risk, PMID 25042860

How to Appeal a Medicaid Denial of Leqvio

A Medicaid denial of Leqvio triggers a specific administrative process that is distinct from commercial insurance appeals. Patients and prescribers have more procedural protections than most people realize.

Step 1: Request a redetermination. After receiving a denial notice, the patient or prescriber has the right to request an internal redetermination from the Medicaid managed care organization (MCO) or the state Medicaid agency directly, depending on whether the patient is enrolled in managed care. The redetermination request must typically be filed within 30 to 60 days of the denial date (varies by state). Submit the complete PA documentation set listed above plus a formal letter of medical necessity signed by the treating physician.

Step 2: File for a fair hearing. If the redetermination is denied, the patient has a federal right to a fair hearing before a state administrative law judge under 42 CFR § 431.220. 42 CFR 431.220 CMS The hearing request window is generally 90 days from the date of the adverse action notice. The patient can request a continuation of benefits pending the hearing, which may allow continued access if the drug was previously approved.

Step 3: Prepare the hearing record. The hearing record should include the treating physician's clinical notes, the two relevant trial publications (ORION-10 and ORION-11), PMID 32187462 the ACC/AHA guideline Class IIa recommendation, PMID 35953146 a letter from the prescribing cardiologist or lipidologist explaining why inclisiran is medically necessary for this specific patient, and any peer-reviewed evidence that the denied step therapy drug is contraindicated or insufficient.

Step 4: Escalate to CMS if the denial appears to violate federal law. Medicaid programs cannot exclude a drug from coverage simply because of cost if the drug is medically necessary and meets federal requirements. If a state's blanket exclusion of PCSK9 inhibitors appears to conflict with 42 U.S.C. § 1396r-8 (the Medicaid drug rebate statute), a complaint can be filed with CMS. This route is slow but has resulted in formulary revisions in two states since 2022.

A 2023 study in Circulation found that patients who completed the full appeals process for PCSK9 inhibitor denials achieved final approval in 54 percent of cases. PCSK9 appeals outcomes, PMID 36780393 That figure underscores why pursuing the appeal rather than abandoning the request is often the right clinical choice.

Formulary Tier and Cost Without Coverage

On state Medicaid formularies that do list Leqvio, the drug typically lands on a non-preferred specialty tier, which in Medicaid terms usually means prior authorization is required before dispensing and the state pays the negotiated Medicaid rebate price rather than the list price.

The Medicaid rebate on inclisiran is governed by the Inflation Reduction Act (IRA) provisions and the standard basic rebate formula under 42 U.S.C. § 1396r-8. The statutory minimum rebate for a single-source brand drug is 23.1 percent of the Average Manufacturer Price (AMP). Medicaid Drug Rebate Program, CMS That means the state pays substantially less than the $6,500-per-dose list price, which is part of the economic argument prescribers can make in value-based coverage discussions with state DUR boards.

For patients paying out of pocket without any coverage, the cash price averages approximately $540 per month (annualized from the $3,250 per dose, two-dose-per-year schedule). Leqvio FDA label, accessdata.fda.gov That cost is prohibitive for virtually every Medicaid-eligible patient, which reinforces the argument that coverage denial is not a minor inconvenience but a barrier to guideline-directed cardiovascular care.

GoodRx and similar discount programs apply only to retail pharmacy dispensing. Because Leqvio is administered in a physician's office or infusion center and billed under the medical benefit (J-code J3490 or J3590, or the specific J1305 code assigned in 2023), retail discount cards do not apply. CMS HCPCS code for inclisiran Patients should not be advised to seek GoodRx pricing for this drug.

The Manufacturer Savings Card: Why Medicaid Patients Cannot Use It

Novartis offers the Leqvio ARCH program for commercially insured patients, which can reduce out-of-pocket costs to as low as $0 per dose. Medicaid patients are categorically excluded. This exclusion is not a company policy choice. It is a legal requirement under the federal anti-kickback statute, 42 U.S.C. § 1320a-7b(b), which prohibits offering anything of value to induce a federal healthcare program beneficiary to use a particular drug or service. OIG anti-kickback guidance

Prescribers sometimes receive questions from patients who have seen manufacturer advertising for the savings program. The direct answer is: Medicaid patients are not eligible, and using the card would constitute a federal violation. The correct path is the Medicaid PA and appeal process described above.

For patients who lose Medicaid eligibility and transition to a marketplace plan or commercial coverage, the savings card eligibility should be reassessed at that point. Novartis patient assistance programs (PAPs) may also provide free drug for uninsured patients who meet income thresholds. NeedyMeds database is one public resource for confirming current PAP availability, though prescribers should contact Novartis directly for the most current program terms.

What Medicaid Does Cover for Lipid Lowering: Context for Prescribers

Every state Medicaid program covers high-intensity statins. Atorvastatin 40-80 mg and rosuvastatin 20-40 mg are on virtually all state preferred drug lists at the lowest cost-sharing tier. CMS Medicaid preferred drug list resources

Ezetimibe 10 mg is covered by most state Medicaid programs, generally as a generic (available since 2017) at minimal cost to the patient. The SHARP trial (N=9,270) showed ezetimibe plus simvastatin reduced major vascular events by 17 percent versus placebo in chronic kidney disease patients. SHARP trial, PMID 21663949 Documenting a completed ezetimibe trial is therefore both good clinical care and a necessary step for Medicaid PA.

Bempedoic acid (Nexletol, 180 mg daily) is covered by a growing number of state Medicaid programs after demonstrating a 13 percent reduction in major adverse cardiovascular events in the CLEAR Outcomes trial (N=13,970) published in the New England Journal of Medicine in 2023. CLEAR Outcomes, PMID 36876740 Prescribers should check state PDLs for bempedoic acid coverage before assuming it is available as a step therapy agent, since some states that require it as a step have not yet added it to the formulary, which creates a documented exception opportunity.

Bile acid sequestrants (cholestyramine, colesevelam) are covered by nearly all state Medicaid programs. Their LDL-C reduction of 15 to 30 percent is modest, and gastrointestinal tolerability limits adherence, but they appear on some state step therapy lists as required agents. Colesevelam efficacy, PMID 12742809

Icosapent ethyl (Vascepa, 4 g daily) is approved for ASCVD risk reduction in patients with hypertriglyceridemia. The REDUCE-IT trial (N=8,179) showed a 25 percent relative risk reduction in major cardiovascular events versus placebo. REDUCE-IT, PMID 30145824 Coverage under Medicaid varies. Icosapent ethyl does not reduce LDL-C and therefore does not substitute for inclisiran in the PA step therapy sequence, but it may appear on Medicaid formularies as an adjunct agent for patients with both high LDL-C and hypertriglyceridemia.

Leqvio and Weight Loss: Clarifying a Common Misconception

Several patients and some referring providers ask whether Leqvio can be prescribed for weight loss. It cannot. Inclisiran is a PCSK9 inhibitor. It has no mechanism of action related to weight regulation, appetite, or metabolic rate. The FDA has not approved it for weight management, and no clinical trial has evaluated it for that indication. FDA inclisiran approval

The confusion may arise because patients researching GLP-1 receptor agonists (semaglutide, tirzepatide) and PCSK9 inhibitors sometimes conflate the two drug classes when searching for coverage information. These are entirely separate drug classes with separate indications, separate PA criteria, and separate formulary placements. A Medicaid patient who needs both LDL-C lowering and weight management requires two separate PA processes.

Less than half of state Medicaid programs currently cover GLP-1 receptor agonists for obesity, though coverage for GLP-1s approved for type 2 diabetes is near-universal. GLP-1 Medicaid coverage, PMID 37556295 Neither the weight-loss GLP-1 coverage rate nor the inclisiran coverage rate should be applied to the other drug class.